Our advantage R&D of Innovative drug based on the results of pharmacokinetic ————
NEW New First-in-class R&D The layout of the development of innovative drugs that are First-in-class is based on a clinical value-oriented and global perspective, as per the 'visual XDC' drug development concept.
MULTI Multi a large number and a variety of nuclide labeling and CMC experience Extensive expertise in the labeling of numerous compounds, including small molecules, peptides, and other macromolecules; Extensive involvement in a multitude of R&D projects; Possessing significant experience in nuclear drug CMC development.
FAST Fast pathway to rapid clinical translation A number of clinical translation centers were laid out for rapid clinical proof of concept to make "Go" or "No Go" decisions, and the translation speed and efficiency can be comparable to those of global clinical institutions.
PATENT Autonomous global patent arrangement We have professionals who hold qualifications in patent agency, enabling them to conduct global PCT and strategic layout of platform technologies and pipeline products.
COMPREHENSIVE Comprehensive Layout of the whole industrial chain Nuclear drug R&D, nuclide linker design, antibody transformation, and the establishment of a complete nuclear drug equipment industry chain to filling the gap in high-end nuclear drug and automation equipment development.
86-0510-88786189
